Literature DB >> 15304390

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks.

Michal O Nowicki1, Rafal Falinski, Mateusz Koptyra, Artur Slupianek, Tomasz Stoklosa, Ewa Gloc, Margaret Nieborowska-Skorska, Janusz Blasiak, Tomasz Skorski.   

Abstract

The oncogenic BCR/ABL tyrosine kinase induces constitutive DNA damage in Philadelphia chromosome (Ph)-positive leukemia cells. We find that BCR/ABL-induced reactive oxygen species (ROSs) cause chronic oxidative DNA damage resulting in double-strand breaks (DSBs) in S and G(2)/M cell cycle phases. These lesions are repaired by BCR/ABL-stimulated homologous recombination repair (HRR) and nonhomologous end-joining (NHEJ) mechanisms. A high mutation rate is detected in HRR products in BCR/ABL-positive cells, but not in the normal counterparts. In addition, large deletions are found in NHEJ products exclusively in BCR/ABL cells. We propose that the following series of events may contribute to genomic instability of Ph-positive leukemias: BCR/ABL --> ROSs --> oxidative DNA damage --> DSBs in proliferating cells --> unfaithful HRR and NHEJ repair.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304390     DOI: 10.1182/blood-2004-05-1941

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  86 in total

1.  Inhibition of the NADPH oxidase regulates heme oxygenase 1 expression in chronic myeloid leukemia.

Authors:  Melissa M Singh; Mary E Irwin; Yin Gao; Kechen Ban; Ping Shi; Ralph B Arlinghaus; Hesham M Amin; Joya Chandra
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

2.  Genomic instability in chronic myeloid leukemia: targets for therapy?

Authors:  N Muvarak; P Nagaria; F V Rassool
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

3.  Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Authors:  L A Tobin; C Robert; A P Rapoport; I Gojo; M R Baer; A E Tomkinson; F V Rassool
Journal:  Oncogene       Date:  2012-05-28       Impact factor: 9.867

Review 4.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress.

Authors:  M Koptyra; K Cramer; A Slupianek; C Richardson; T Skorski
Journal:  Leukemia       Date:  2008-04-10       Impact factor: 11.528

6.  Glutathione S-transferase gene polymorphisms and susceptibility to chronic myeloid leukemia.

Authors:  Hai-rong He; Xiao-xia Zhang; Jin-yue Sun; Sa-sa Hu; Ying Ma; Ya-lin Dong; Jun Lu
Journal:  Tumour Biol       Date:  2014-06

7.  BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.

Authors:  Mirle Schemionek; Christian Elling; Ulrich Steidl; Nicole Bäumer; Ashley Hamilton; Tilmann Spieker; Joachim R Göthert; Martin Stehling; Amy Wagers; Claudia S Huettner; Daniel G Tenen; Lara Tickenbrock; Wolfgang E Berdel; Hubert Serve; Tessa L Holyoake; Carsten Müller-Tidow; Steffen Koschmieder
Journal:  Blood       Date:  2010-01-06       Impact factor: 22.113

8.  BCR/ABL downregulates DNA-PK(CS)-dependent and upregulates backup non-homologous end joining in leukemic cells.

Authors:  Tomasz Poplawski; Janusz Blasiak
Journal:  Mol Biol Rep       Date:  2009-08-21       Impact factor: 2.316

Review 9.  Redox control of leukemia: from molecular mechanisms to therapeutic opportunities.

Authors:  Mary E Irwin; Nilsa Rivera-Del Valle; Joya Chandra
Journal:  Antioxid Redox Signal       Date:  2012-09-28       Impact factor: 8.401

Review 10.  Molecular biology of bcr-abl1-positive chronic myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Blood       Date:  2008-09-30       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.